HIV Drugs: Trigger of Autoimmunity
Implicit, severe immune sensitive reactions to the anti-HIV drug abacavir materialize through an autoimmune procedure, resulting from the design of drug-induced immunizing agent that are attacked by the body's immune system as all HIV Drugs blocks protein synthesis and enzymes which cause alteration in and enzyme synthesis, autoimmune deformities accrue in HIV Patient and proteins. Many times foreign myalgia’s and arthralgia’s occur in about 5% of patients with HIV, sometimes in association with HIV seroconversion. Many bone related diseases and HIV-associated arthralgia started progresses towards inflammatory joint disease and disorders because of HIV Treatment.
Related Conference of HIV Drugs: Trigger of Autoimmunity
13th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
HIV Drugs: Trigger of Autoimmunity Conference Speakers
Recommended Sessions
- Autoimmune Diseases
- Autoimmunity and Transplantation
- Bioinformatics and Autoimmunity
- Cancer Immunology
- Clinical Autoimmunity: Current & Future Research
- Cytokine and Current Research
- Genetic Engineering & Therapeutics
- HIV Drugs: Trigger of Autoimmunity
- Immunometabolism and Autoimmunity
- Inherited Autoimmunity
- Lupus
- Molecular Immunology
- Ocular Autoimmunity
- Pathophysiology and Autoimmunity
- Pediatric Autoimmunity
Related Journals
Are you interested in
- Antibiotic Prophylaxis - Antibiotics 2026 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2026 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2026 (UK)
- Antibiotics - Antibiotics 2026 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2026 (UK)
- Antimicrobial Peptides - Antibiotics 2026 (UK)
- Antimicrobial Therapy - Antibiotics 2026 (UK)
- Cancer Immunology and Immunotherapy - European Immunology 2025 (Italy)
- Clinical Trials of Antibiotics - Antibiotics 2026 (UK)
- Current Research in Antibiotic Resistance - Antibiotics 2026 (UK)
- Developing Alternatives to Antibiotics - Antibiotics 2026 (UK)
- Diagnostic and Technological Novelty of Immunology - European Immunology 2025 (Italy)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2026 (UK)
- Epidemiology - European Immunology 2025 (Italy)
- Immune System - European Immunology 2025 (Italy)
- Immunodeficiency - European Immunology 2025 (Italy)
- Immunogenetics - European Immunology 2025 (Italy)
- Immunoinformatics & Systems Immunology - European Immunology 2025 (Italy)
- Immunological Techniques - European Immunology 2025 (Italy)
- Immunology - European Immunology 2025 (Italy)
- Immunology & Vaccines - Antibiotics 2026 (UK)
- Immunotherapy - European Immunology 2025 (Italy)
- Immunotoxicology - European Immunology 2025 (Italy)
- Infectious Diseases - Antibiotics 2026 (UK)
- Mechanisms and Evolution of Antibiotic Resistance - Antibiotics 2026 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2026 (UK)
- Microorganisms Producing Antibiotics - Antibiotics 2026 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Neuroimmunology - European Immunology 2025 (Italy)
- New antibiotics and non-antibiotic approaches - Antibiotics 2026 (UK)
- Parasite Immunology - European Immunology 2025 (Italy)
- Pediatrics Immunology - European Immunology 2025 (Italy)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2026 (UK)
- Pharmacology & Toxicology - Antibiotics 2026 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2026 (UK)
- Reproductive Immunology - European Immunology 2025 (Italy)
- The Next Generation Approach of Antibiotics - Antibiotics 2026 (UK)
- Transplantation Immunology - European Immunology 2025 (Italy)
- Viral Immunology - European Immunology 2025 (Italy)